Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 360 mg - capsule, modified release - excipient ingredients: methacrylic acid copolymer; diethyl phthalate; sodium lauryl sulfate; purified talc; povidone; simethicone; tributyl acetylcitrate; maize starch; sucrose; titanium dioxide; brilliant blue fcf; potable water; gelatin; silicon dioxide - vasocardol cd is indicated for the treatment of hypertension. vasocardol cd is also indicated for the management of chronic stable angina (effort associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina have not been substantiated, use of this formulation for these indications is not recommended.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 360 mg - capsule, modified release - excipient ingredients: purified talc; methacrylic acid copolymer; povidone; tributyl acetylcitrate; sodium lauryl sulfate; diethyl phthalate; simethicone; maize starch; sucrose; titanium dioxide; brilliant blue fcf; potable water; gelatin; silicon dioxide - cardizem cd is indicated for the treatment of hypertension. cardizem cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina has not been substantiated, use of this formulation for these indications is not recommended.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 240 mg - capsule, modified release - excipient ingredients: gelatin; brilliant blue fcf; ethylcellulose; titanium dioxide; tributyl acetylcitrate; castor oil; methacrylic acid copolymer; stearic acid; purified talc; fumaric acid; simethicone; white beeswax; colloidal anhydrous silica; maize starch; sucrose - vasocardol cd is indicated for the treatment of hypertension. vasocardol cd is also indicated for the management of chronic stable angina (effort associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina have not been substantiated, use of this formulation for these indications is not recommended

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 180 mg - capsule, modified release - excipient ingredients: purified talc; fumaric acid; gelatin; methacrylic acid copolymer; stearic acid; simethicone; white beeswax; castor oil; ethylcellulose; tributyl acetylcitrate; brilliant blue fcf; titanium dioxide; colloidal anhydrous silica; maize starch; sucrose - vasocardol cd is indicated for the treatment of hypertension. vasocardol cd is also indicated for the management of chronic stable angina (effort associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina have not been substantiated, use of this formulation for these indications is not recommended

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 240 mg - capsule, modified release - excipient ingredients: gelatin; ethylcellulose; methacrylic acid copolymer; colloidal anhydrous silica; titanium dioxide; white beeswax; tributyl acetylcitrate; castor oil; stearic acid; purified talc; simethicone; brilliant blue fcf; fumaric acid; maize starch; sucrose - cardizem cd is indicated for the treatment of hypertension. cardizem cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina have not been substantiated, use of this formulation for these indications is not recommended.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 180 mg - capsule, modified release - excipient ingredients: colloidal anhydrous silica; methacrylic acid copolymer; titanium dioxide; stearic acid; fumaric acid; tributyl acetylcitrate; castor oil; simethicone; ethylcellulose; purified talc; brilliant blue fcf; gelatin; white beeswax; maize starch; sucrose - cardizem cd is indicated for the treatment of hypertension. cardizem cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina have not been substantiated, use of this formulation for these indications is not recommended.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - doxycycline hyclate, quantity: 116.3 mg (equivalent: doxycycline, qty 100 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; purified water; hypromellose phthalate; hyprolose; wheat starch; diethyl phthalate; hypromellose; gelatin; povidone; ethanol; shellac; pharmaceutical glaze; carbon black - indications as at 24 march 2004: doxycycline is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. doxycycline is active against a wide range of gram positive and gram negative organisms. note: the 50 mg capsule is not a paediatric formulation. doryx is indicated in the treatment of infections caused by the following micro-organisms: mycoplasma pneumoniae: primary atypical pneumonia. rickettsiae: queensland tick typhus, typhus fever and q fever agents of psittacosis. calymmatobacterium (donovania) granulomitis: granuloma inguinale. agents of lymphogranuloma venereum. borreliae: relapsing fever. chlamydia trachomatis. doryx is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doryx alone, or in combination with topical agents. doryx is indicated in the treatment of infections caused by the following gram negative micro-or

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - doxycycline hyclate, quantity: 58.15 mg (equivalent: doxycycline, qty 50 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; povidone; magnesium stearate; hypromellose; gelatin; diethyl phthalate; hypromellose phthalate; lactose monohydrate; purified water; wheat starch; hyprolose; ethanol; shellac; pharmaceutical glaze; carbon black - indications as at 24 march 2004: doxycycline is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. doxycycline is active against a wide range of gram positive and gram negative organisms. note: the 50 mg capsule is not a paediatric formulation. doryx is indicated in the treatment of infections caused by the following micro-organisms: mycoplasma pneumoniae: primary atypical pneumonia. rickettsiae: queensland tick typhus, typhus fever and q fever agents of psittacosis. calymmatobacterium (donovania) granulomitis: granuloma inguinale. agents of lymphogranuloma venereum. borreliae: relapsing fever. chlamydia trachomatis. doryx is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doryx alone, or in combination with topical agents. doryx is indicated in the treatment of infections caused by the following gram negative micro-or

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 200 mg - capsule, hard - excipient ingredients: purified water; lactose monohydrate; maize starch; patent blue v; magnesium stearate; titanium dioxide; erythrosine; gelatin; colloidal anhydrous silica; sodium lauryl sulfate - fluconazole apotex (fluconazole) capsules, given orally, are indicated for the following conditions: - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the acute phase of cryptococcal meningitis. - maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. - treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. - secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. - serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infecctions. until such data are available, amphotericin b remains the drug of choice. - vaginal candidiasis, when topical therapy has failed. - treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therpy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - lansoprazole, quantity: 30 mg - capsule - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); hypromellose; indigo carmine; colloidal anhydrous silica; titanium dioxide; maize starch; purified talc; macrogol 300; sucrose; carmoisine; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - adults:. lanzopran capsules are indicated for. - healing and long-term management of reflux oesophagitis. . - healing and long-term management for patients with duodenal ulcer.. - healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . - patients with benign peptic lesions that do not respond to h2-receptor antagonists.. - eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics. . - relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric and adolescent patients i to 17 years of age:. lanzopran capsules are indicated for. - treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . - healing of erosive oesophagitis.